THE DEAL, AT A GLANCE
2/4 reviewedCellsBin
CellsBin
CellsBin detects and profiles rare cells in blood to support precision diagnostics, therapy monitoring and research.
CellsBin raised Series A, announced 2026-10-0201What it doesCellsBin detects and profiles rare cells in blood to support precision diagnostics, therapy monitoring and research.Source-grounded · automated review · Explore ↗
Checked 2026-10-06 · Review due 2026-10-13
Read supporting source ↗Ultrasensitive detection, single-cell profiling, and…
02Who is involvedBacked by 108 BioCapitalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedCellsBin raised Series A, announced 2026-10-02From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersIts rare-cell tools could help researchers track therapy response and disease progression from small cell signals.Interpretation · Explore ↗
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
CellsBin · Financing Record
Explore source-linked visual explanations for CellsBin. Unsupported claims are withheld while source review continues.
Record 13244 · Recorded date: 2026-10-02
Explore company records →